Through combination analyses of both the WES and RNA-seq data, we first evaluated the differences in gene mutations, CNVs, gene expression, signaling pathways, and cellular components between tumors before and after treatment in primary BC, then examined the key molecular features related to NAC sensitivity of BC, and successfully identified CDKAL1P409L, ADGRA2 and ADRB3 as novel biomarkers for the selection of patients for NAC. The gene discussed is ADGRA2; the disease is breast cancer.